Antibody Information
General Information of This Antibody
| Antibody ID | ANI0MJOHL |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-ALK mAb DX-0125 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | ALK tyrosine kinase receptor (ALK) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CDX-0125-TEI [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 10.13% (Day 15) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
The in vivo efficacy of CDX-0125-TEI was evaluated in female CB17 SCID mice bearing COG-N-424x (ALK wild-type). Upon enrollment, mice (n = 10 per group) were intraperitoneally injected with 10 mg/kg CDX-0125-TE on day 0 of enrollment and on day 7.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: COG-N-424x) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 15.15% (Day 21) | Moderate ALK expression (ALK++) | ||
| Method Description |
Mice (n = 10 per group) were intraperitoneally injected with the following drugs: IgG, unconjugated CDX-0125, or CDX-0125-TEI once a week for two consecutive weeks at a range of doses 1 mg/kg.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: ALK F1174L) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 39.21% (Day 19) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
Mice (n = 10 per group) were intraperitoneally injected with the following drugs: IgG, unconjugated CDX-0125, or CDX-0125-TEI once a week for two consecutive weeks at a range of doses 1 mg/kg.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: ALK F1245C) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 44.99% (Day 19) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
Mice (n = 10 per group) were intraperitoneally injected with the following drugs: IgG, unconjugated CDX-0125, or CDX-0125-TEI once a week for two consecutive weeks at a range of doses 3 mg/kg.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: ALK F1245C) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 54.55% (Day 21) | Moderate ALK expression (ALK++) | ||
| Method Description |
Mice (n = 10 per group) were intraperitoneally injected with the following drugs: IgG, unconjugated CDX-0125, or CDX-0125-TEI once a week for two consecutive weeks at a range of doses 3 mg/kg.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: ALK F1174L) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.66% (Day 21) | Moderate ALK expression (ALK++) | ||
| Method Description |
Mice (n = 10 per group) were intraperitoneally injected with the following drugs: IgG, unconjugated CDX-0125, or CDX-0125-TEI once a week for two consecutive weeks at a range of doses 10 mg/kg.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: ALK F1174L) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 85.83% (Day 19) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
Mice (n = 10 per group) were intraperitoneally injected with the following drugs: IgG, unconjugated CDX-0125, or CDX-0125-TEI once a week for two consecutive weeks at a range of doses 10 mg/kg.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: ALK F1245C) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.39% (Day 15) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
The in vivo efficacy of CDX-0125-TEI was evaluated in female CB17 SCID mice bearing COG-N-424x (ALK wild-type). Upon enrollment, mice (n = 10 per group) were intraperitoneally injected with 15 mg/kg CDX-0125-TE on day 0 of enrollment and on day 7.
|
||||
| In Vivo Model | Neuroblastoma PDX model (PDX: COG-N-424x) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 11.43% (Day 11) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
The in vivo efficacy of CDX-0125-TEI was evaluated in female CB17 SCID mice bearing NBL-S cells (ALK wild-type). Upon enrollment, mice (n = 10 per group) were intraperitoneally injected with 15 mg/kg CDX-0125-TE on day 0 of enrollment and on day 7.
|
||||
| In Vivo Model | NBL-S CDX model | ||||
| In Vitro Model | Neuroblastoma | NBL-S cells | CVCL_2136 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.71% (Day 11) | Positive ALK expression (ALK+++/++) | ||
| Method Description |
The in vivo efficacy of CDX-0125-TEI was evaluated in female CB17 SCID mice bearing NBL-S cells (ALK wild-type). Upon enrollment, mice (n = 10 per group) were intraperitoneally injected with 15 mg/kg CDX-0125-TE on day 0 of enrollment and on day 7.
|
||||
| In Vivo Model | NBL-S CDX model | ||||
| In Vitro Model | Neuroblastoma | NBL-S cells | CVCL_2136 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
4.70 pM
|
Positive ALK expression (ALK+++/++) | ||
| Method Description |
Cells were seeded at 2000 cells per well in black 96-well proliferation plates and dosed with a titration of conjugates for 3 to 5 days, until control untreated cells reached 80 to 90% confluence.
|
||||
| In Vitro Model | Neuroblastoma | IMR-32 cells | CVCL_0346 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.80 pM
|
Positive ALK expression (ALK+++/++) | ||
| Method Description |
Cells were seeded at 2000 cells per well in black 96-well proliferation plates and dosed with a titration of conjugates for 3 to 5 days, until control untreated cells reached 80 to 90% confluence.
|
||||
| In Vitro Model | Buccal mucosa squamous cell carcinoma | NB-1 cells | CVCL_GZ01 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
21.70 pM
|
Moderate ALK expression (ALK++) | ||
| Method Description |
Cells were seeded at 2000 cells per well in black 96-well proliferation plates and dosed with a titration of conjugates for 3 to 5 days, until control untreated cells reached 80 to 90% confluence.
|
||||
| In Vitro Model | Neuroblastoma | SK-N-SH cells | CVCL_0531 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000 pM | Negative ALK expression (ALK-) | ||
| Method Description |
Cells were seeded at 2000 cells per well in black 96-well proliferation plates and dosed with a titration of conjugates for 3 to 5 days, until control untreated cells reached 80 to 90% confluence.
|
||||
| In Vitro Model | Neuroblastoma | SK-N-AS cells | CVCL_1700 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.